Amryt Pharma plc

Chiesi Farmaceutici S.p.A. is actively expanding its rare disease business in Japan through a subsidiary established there in 2022 and as part of the family-owned Italian firm's global push into this

Egetis Therapeutics AB could soon join the list of promising rare disease biotechs acquired by pharma firms now that the Swedish group has confirmed talks have been held with prospective buyers. Foll

Chiesi Farmaceutici S.p.A. is revisiting its respiratory heritage, teaming up with Sweden's Affibody AB to develop inhaled drugs in a deal that could be worth over $640m. Under the terms of the agr

Despite the announcement of three significant M&A deals on the first day of this year’s J.P. Morgan Healthcare Conference, the boost to health care stocks that often accompanies the meeting has not ye